Nature Genetics
16, 260 - 264 (1997)
doi:10.1038/ng0797-260
Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3Marta Chesi1, Elena Nardini2, Leslie A. Brents1, Evelin Schröck3, Thomas Ried3, W. Michael Kuehl1, 4
& P. Leif Bergsagel2
1Genetics Department, Medicine Branch, National Cancer Institute, Bethesda, Maryland 20889-5105, USA.
2Department of Medicine, Division of Hematology and Oncology, Cornell University Medical College, New York NY, 10021, USA.
3Diagnostic Development Branch, National Center for Human Genome Research, National Institutes of Health, Bethesda, Maryland 20892-4470, USA.
4e-mail: wmk@helix. nih.gov. Dysregulation of oncogenes by translocation to the IgH locus (14q32) is a seminal event in the pathogenesis of B-cell tumours1. In multiple myeloma (MM), translations to the IgH locus have been reported at an incidence of 20−60%. For most translocations, the partner chromosome is unknown (14q+); for the others, a diverse array of chromosomal partners have been identified, with 11q13 (cyclin D1) the only chromosome that is frequently involved2−6. Recently, we developed a Southern-blot assay that detects translocation breakpoint fragments in most MM tumours, including those with no translocation detected by conventional karyotyping6. In a continuing analysis of translocations in 21 myeloma cell lines and primary tumours, we show that the novel, karyotypically silent translocation t(4;14)(p16.3;q32.3) is present in five lines and at least three of ten primary tumours. The chromosome-4 breakpoints are clustered in a 70-kb region centromeric to the f ibroblast growth factor receptor 3 gene (FGFR3), the apparent dysregulated oncogene. Two lines and one primary tumour with this translocation selectively express an FGFR3 allele containing activating mutations identified previously in thanatophoric dwarfism. We propose that after the t(4;14) translocation, somatic mutation during tumour progression frequently generates an FGFR3 protein that is active in the absence of ligand.
REFERENCES
- Korsmeyer, S.J. Chromosomal translations in lymphoid malignancies reveal novel proto-oncogenes. Annu. Rev. Immunol. 10, 785−607 (1992). | Article | PubMed | ISI | ChemPort |
- Taniwaki, M. et al. Nonrandom chromosomal rearrangements of 14q32.3 and 19p13.3 and preferential deletion of 1p in 21 patients with multiple myeloma and plasma cell leukemia. Blood 84, 2283−2290 (1994). | PubMed | ISI | ChemPort |
- Sawyer, J.R., Waldron, J.A., Jagannath, S. & Barlogie, B. Cytogenetic findings in 200 patients with multiple myeloma. Cancer Genet. Cytogenet. 82, 41−49 (1995). | Article | PubMed | ISI | ChemPort |
- Lai, J.L. et al. Improved cytogenetics in multiple-myeloma—a study of 151 patients including 117 patients at diagnosis. Blood 85, 2490−2497 (1995). | PubMed | ISI | ChemPort |
- Chesi, M. et al. Dysregulation of Cyclin D1 by translocation into an IgH gamma switch region in two multiple myeloma cell lines. Blood 88, 674−681 (1996). | PubMed | ISI | ChemPort |
- Bergsagel, P.L. et al. Promiscuous translations into IgH switch regions in multiple myeloma. Proc. Natl. Sci. Acad. USA 93, 13931−13936 (1996). | Article | ChemPort |
- Baxendale, S. et al. A cosmid contig and high resolution restriction map of the 2 megabase region containing the Huntington's disease gene. Nature Genet. 4, 181−186 (1993). | PubMed | ISI | ChemPort |
- Keegan, K., Johnson, D., William, L.T. & Hayman, M.J. Isolation of an additional member of the fibroblast growth factor receptor family, FGFR-3. Proc. Natl. Acad Sci. USA 88, 1095−1099(1991). | PubMed | ChemPort |
- Keegan, K., Meyer, S. & Hayman, M.J. Structural and biosynthetic characterization of the fibroblast growth factor receptor 3 (FGFR-3) protein. Oncogene 6, 2229−2236 (1991). | PubMed | ISI | ChemPort |
- Muenke, M. & Schell, U. Fibroblast-growth-factor-receptor mutations in human sketetal disorders. Trends Genet. 11, 308−313 (1995). | Article | PubMed | ISI | ChemPort |
- Naski, M.C., Wang, Q., Xu, J. & Ornitz, D.M. Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia. Nature Genet. 13, 233−237 (1996). | Article | PubMed | ISI | ChemPort |
- Webster, M.K., D'Avis, P.Y., Robertson, S.C. & Donoghue, D.J. Profound ligand-independent kinase activation of fibroblast growth factor receptor 3 by the activation loop mutation responsible for a lethal skeletal dysplasia, thanatophoric dysplasia type II. Mol. Cell. Biol. 16, 4081−4087 (1996). | PubMed | ISI | ChemPort |
- Webster, M.K. & Donoghue, D.J. Constitutive activation of fibroblast growth factor receptor 3 by the transmembrane domain point mutation found in achondroplasia. EMBO J. 15, 520−527 (1996). | PubMed | ISI | ChemPort |
- Rousseau, F. et al. Missense FGFR3 mutations create cysteine residues in thanatophoric dwarfism typeI (TD1). Hum. Mol. Genet. 5, 509−512 (1996). | Article | PubMed | ISI | ChemPort |
- Francomano, C.A. et al. A new skeletal dysplasia with severe tibial bowing, profound developmental delay and acanthosis nigricans is caused by a Lys 650 Met mutation in fibroblast growth factor receptor 3 (FGFR3). Am. J. Hum. Genet. 59, A25 (1996).
- Tavormina, P.L. et al. Thanatophoric dysplasia (types I and II) caused by distinct mutations in fibroblast growth factor receptor 3. Nature Genet. 9, 321−328 (1995). | Article | PubMed | ISI | ChemPort |
- Williams, M.E., Swerdlow, S.H. & Meeker, T.C. Chromosome t(11;14)(q13;q32) breakpoints in centrocytic lymphoma are highly localized at the bcl-1 major translocation cluster. Leukemia 7, 1437−1440 (1993). | PubMed | ISI | ChemPort |
- Tsujimoto, Y. et al. Clustering of breakpoints on chromosome 11 in human B-cell neoplasms with the t(11;14) chromosome translocation. Nature 315, 340−343 (1985). | PubMed | ISI | ChemPort |
- de Boer, C.J. et al. Multiple breakpoints within the BCL-1 locus in B-cell lymphoma: rearrangements of the cyclin D1 gene. Cancer Res. 53, 4148−4152 (1993). | PubMed | ChemPort |
- Mason, I.J. The ins and outs of fibroblast growth factors. Cell 78, 547−552 (1994). | PubMed | ISI | ChemPort |
- Su, W.S. et al. Activation of Stat1 by mutant fibroblast growth-factor receptor in thanatophoric dysplasia type II dwarfism. Nature 386, 288−292 (1997). | Article | PubMed | ISI | ChemPort |
- Colvin, J.S., Bohne, B.A., Harding, G.W., McEwen, D.G. & Ornitz, D.M. Skeletal overgrowth and deafness in mice lacking fibroblast growth factor receptor 3. Nature Genet. 12, 390−397 (1996). | Article | PubMed | ISI | ChemPort |
- Deng, C., Wynshaw-Boris, A., Zhou, F., Kuo, A. & Leder, P. Fibroblast growth factor receptor 3 is a negative regulator of bone growth. Cell 84, 911−921 (1996). | Article | PubMed | ISI | ChemPort |
- Ornitz, D.M. & Leder, P. Ligand specificity and heparin dependence of fibroblast growth factor receptors 1 and 3. J. Biol. Chem. 267, 16305−16311 (1992). | PubMed | ISI | ChemPort |
- Caligaris-Cappio, F. et al. Role of bone marrow stromal cells in the growth of human multiple myeloma. Blood 77, 2688−2693 (1991). | PubMed | ChemPort |
- Allouche, M. Basic fibroblast growth factor and hematopoiesis. Leukemia 9, 937−942 (1995). | PubMed | ISI | ChemPort |
- Shiang, R. et al. Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasia. Cell 78, 335−342 (1994). | Article | PubMed | ISI | ChemPort |
- Johnston, C.L., Cox, H.C., Gomm, J.J. & Coombes, R.C. Fibroblast growth factor receptors (FGFRs) localize in different cellular compartments. J. Biol. Chem. 270, 30643−30650 (1995). | Article | PubMed | ISI | ChemPort |
- Schröck, E. et al. Multicolor spectral karyotyping of human chromosomes. Science 273, 494−497 (1996). | PubMed | ISI |
- Kuehl, W.M., Brents, L.A., Chesi, M. & Bergsagel, P.L. Selective expression of one c-myc allele in two human myeloma cell lines. Cancer Res. 56, 4370−4373 (1996). | PubMed | ISI | ChemPort |
- Davis, L.G., Kuehl, W.M. & Battey, J.F., Methods in Molecular Biology (Appleton & Lange, Norwalk, Connecticut, 1994).
|
